Constanze Burak1, Verena Brüll1, Peter Langguth2, Benno F Zimmermann3,4, Birgit Stoffel-Wagner5, Udo Sausen6, Peter Stehle1, Siegfried Wolffram7, Sarah Egert8. 1. Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn, Endenicher Allee 11-13, 53115, Bonn, Germany. 2. Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. 3. Institut Prof. Dr. Georg Kurz GmbH, Cologne, Germany. 4. Department of Nutrition and Food Sciences, Food Technology and Food Biotechnology, University of Bonn, Bonn, Germany. 5. Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany. 6. Department of Anaesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. 7. Institute of Animal Nutrition and Physiology, Christian-Albrechts-University Kiel, Kiel, Germany. 8. Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn, Endenicher Allee 11-13, 53115, Bonn, Germany. s.egert@uni-bonn.de.
Abstract
PURPOSE: To investigate the plasma kinetics of quercetin derived from hard capsules filled with onion skin extract powder or quercetin dihydrate in humans. METHODS: In a randomized, single-blind, diet-controlled crossover study, 12 healthy subjects (six men and six women) aged 21-33 years were administered a single oral supra-nutritional dose of approximately 163 mg quercetin derived from onion skin extract powder (containing 95.3 % of total flavonoids as quercetin aglycone) or quercetin dihydrate (134 mg quercetin aglycone equivalent). Blood samples were collected before and during a 24-h period after quercetin administration. The concentrations of quercetin and its two monomethylated derivatives, isorhamnetin (3'-O-methyl quercetin), and tamarixetin (4'-O-methyl quercetin), were measured using HPLC with fluorescence detection after plasma enzymatic treatment. RESULTS: The systemic availability, determined by comparing the plasma concentration-time curves of quercetin, was 4.8 times higher, and the maximum plasma concentration (C max) was 5.4 times higher after ingestion of the onion skin extract than after ingestion of pure quercetin dihydrate. By contrast, t max did not differ significantly between the two formulations. The C max values for isorhamnetin and tamarixetin were 3.8 and 4.4 times higher, respectively, after administration of onion skin extract than after pure quercetin dihydrate. The plasma kinetics of quercetin were not significantly different in men and women. CONCLUSION: Quercetin aglycone derived from onion skin extract powder is significantly more bioavailable than that from quercetin dihydrate powder filled hard capsules.
RCT Entities:
PURPOSE: To investigate the plasma kinetics of quercetin derived from hard capsules filled with onion skin extract powder or quercetin dihydrate in humans. METHODS: In a randomized, single-blind, diet-controlled crossover study, 12 healthy subjects (six men and six women) aged 21-33 years were administered a single oral supra-nutritional dose of approximately 163 mg quercetin derived from onion skin extract powder (containing 95.3 % of total flavonoids as quercetin aglycone) or quercetin dihydrate (134 mg quercetin aglycone equivalent). Blood samples were collected before and during a 24-h period after quercetin administration. The concentrations of quercetin and its two monomethylated derivatives, isorhamnetin (3'-O-methyl quercetin), and tamarixetin (4'-O-methyl quercetin), were measured using HPLC with fluorescence detection after plasma enzymatic treatment. RESULTS: The systemic availability, determined by comparing the plasma concentration-time curves of quercetin, was 4.8 times higher, and the maximum plasma concentration (C max) was 5.4 times higher after ingestion of the onion skin extract than after ingestion of pure quercetin dihydrate. By contrast, t max did not differ significantly between the two formulations. The C max values for isorhamnetin and tamarixetin were 3.8 and 4.4 times higher, respectively, after administration of onion skin extract than after pure quercetin dihydrate. The plasma kinetics of quercetin were not significantly different in men and women. CONCLUSION:Quercetin aglycone derived from onion skin extract powder is significantly more bioavailable than that from quercetin dihydrate powder filled hard capsules.
Entities:
Keywords:
Bioavailability; Human study; Onion; Quercetin
Authors: Vincent C J de Boer; Ashwin A Dihal; Hester van der Woude; Ilja C W Arts; Siegfried Wolffram; Gerrit M Alink; Ivonne M C M Rietjens; Jaap Keijer; Peter C H Hollman Journal: J Nutr Date: 2005-07 Impact factor: 4.798
Authors: M Harwood; B Danielewska-Nikiel; J F Borzelleca; G W Flamm; G M Williams; T C Lines Journal: Food Chem Toxicol Date: 2007-06-07 Impact factor: 6.023
Authors: Raul Zamora-Ros; Nita G Forouhi; Stephen J Sharp; Carlos A González; Brian Buijsse; Marcela Guevara; Yvonne T van der Schouw; Pilar Amiano; Heiner Boeing; Lea Bredsdorff; Guy Fagherazzi; Edith J Feskens; Paul W Franks; Sara Grioni; Verena Katzke; Timothy J Key; Kay-Tee Khaw; Tilman Kühn; Giovanna Masala; Amalia Mattiello; Esther Molina-Montes; Peter M Nilsson; Kim Overvad; Florence Perquier; M Luisa Redondo; Fulvio Ricceri; Olov Rolandsson; Isabelle Romieu; Nina Roswall; Augustin Scalbert; Matthias Schulze; Nadia Slimani; Annemieke M W Spijkerman; Anne Tjonneland; Maria Jose Tormo; Marina Touillaud; Rosario Tumino; Daphne L van der A; Geertruida J van Woudenbergh; Claudia Langenberg; Elio Riboli; Nicholas J Wareham Journal: J Nutr Date: 2013-12-24 Impact factor: 4.798